Replies to post #17429 on Relief Therapeutics Holding AG (RLFTF)

[nelskof]

Just wait until FDA approval hits. The shares will not be a problem.

[tiggerifficm4]

Well, I like to stay positive...in this case I really need to.

I told Santa I have been good this year!

[trademax42]

hey buddy....pay more attention to the Market Cap (MC) than the # of OS shares. imo

MC for RLTF = 2.53 billion shares X .59 cents = $1.5 billion

CYD*Y recently went to $10 dollars and had an MC = about $5 billion on phase II clinical trials. Right now it has MC = $1.91 billion. Look at the drug's phase II outcomes:

Phase 2 data released August 11, 2020 did not report primary endpoint data (TCSS at Day 14). Day 3 subgroup showed clinical improvement but not mentioned to be statistically significant. Secondary NEWS2 was met. No data on other secondary endpoints.

https://www.biopharmcatalyst.com/company/CYDY

How do you justify close to a $2 billion MC for CYD*Y based on the above phase II outcomes?

Now talk about Remdesivi*r. Read this:

The Emergency Use Approval (EUA) of Remdesivir by the FDA added $10 Billion to Gilead's market cap overnight when it was first announced.

https://seekingalpha.com/article/4367483-relief-therapeutics-discovers-promising-covidminus-19-killer

A $10 billion market cap for an EUA. How does the drug work? Read here:

Remdesivir, the only FDA-authorized drug for COVID-19, may not significantly improve outcomes, a study found

https://www.businessinsider.com/remdesivir-may-not-significantly-improve-covid-19-outcomes-study-2020-8

Now tell me what should the MC for a drug that has demonstrated to show strong outcomes on 19/21 patients. Yes I am talking about RLFTF

Are you still mesmerized by the elephant staring so intently into your eyes?

Quote from your post:

You gotta take care of the elephant in the room staring at you

$RLFTF

Disclaimer: This is just my opinion, do your own dd.